申请人:Md Bioalpha Co., Ltd.
公开号:EP2426212A1
公开(公告)日:2012-03-07
The present invention provides a method capable of effectively treating various diseases associated with energy excess, such as obesity, diabetes, metabolic syndromes, degenerative diseases and mitochrondrial dysfunction-related diseases, via elevation of an NAD(P)+ZNAD(P)H ratio by increasing an NAD(P)+ concentration in vivo or in vitro through use of NAD(P)H as a substrate or coenzyme by oxidoreductase such as NAD(P)H:quinine oxidoreductase (NQO1), a method of screening a drug for the same and a therapeutic drug.
本发明提供了一种能够有效治疗与能量过剩有关的各种疾病的方法,如肥胖症、糖尿病、代谢综合征、退行性疾病和线粒体功能障碍相关疾病,其方法是通过氧化还原酶如NAD(P)H:Quinine oxidoreductase (NQO1))来提高体内或体外的 NAD(P) + 浓度的方法、筛选相同药物的方法以及治疗药物。